13 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $21.3B | $2.4B | 0.0% | 16.5% | $2.5B | — | $2.9B |
| 2024 | $20.7B | $4.1B | 0.0% | 28.8% | $1.1B | — | $3.0B |
| 2023 | $20.6B | $1.3B | 0.0% | 12.2% | $1.6B | — | $1.2B |
| 2022 | $19.2B | $1.0B | 0.0% | 12.2% | $321M | — | $858M |
| 2021 | $19.5B | $1.5B | 0.0% | 14.7% | $910M | — | $2.4B |
| 2020 | $17.6B | — | 0.0% | 11.3% | $2.9B | — | $2.4B |
| 2019 | $18.5B | — | 0.0% | 8.3% | $563M | — | $262M |
| 2018 | $18.3B | — | 0.0% | 8.9% | $432M | — | $411M |
| 2017 | $20.6B | — | 0.0% | 5.4% | $493M | — | $611M |
| 2016 | $21.1B | — | 0.0% | 5.9% | -$317M | — | $716M |
| 2010 | — | $1.1B | — | — | — | $4.1B | $405M |
| 2009 | — | $181M | — | — | — | — | $690M |
| 2008 | — | $25M | — | — | — | — | $507M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $5.4B | $906M | 0.0% | 24.1% | $1.5B | — | $3.0B |
| Dec '25 | $5.5B | $644M | 0.0% | 15.4% | $367M | — | $2.9B |
| Sep '25 | $5.3B | $579M | 0.0% | 16.8% | $778M | — | $3.0B |
| Jun '25 | $5.3B | $522M | 0.0% | 15.6% | $743M | — | $2.6B |
| Mar '25 | $5.2B | $622M | 0.0% | 18.1% | $642M | — | $3.0B |
| Dec '24 | $5.1B | $572M | 0.0% | 16.2% | -$661M | — | $3.0B |
| Sep '24 | $5.1B | $681M | 0.0% | 21.2% | $829M | — | $4.1B |
| Jun '24 | $5.1B | $477M | 0.0% | 14.9% | $602M | — | $2.9B |
| Mar '24 | $5.4B | $2.3B | 0.0% | 61.2% | $346M | — | $2.5B |
| Dec '23 | $5.4B | $456M | 0.0% | 13.7% | $616M | — | $1.2B |
| Sep '23 | $5.1B | $266M | 0.0% | 11.2% | $327M | — | $1.1B |
| Jun '23 | $5.1B | $293M | 0.0% | 11.9% | $466M | — | $934M |
| Mar '23 | $5.0B | $296M | 0.0% | 12.0% | $214M | — | $766M |
| Dec '22 | $5.0B | $274M | 0.0% | 10.7% | $131M | — | $858M |
| Sep '22 | $4.8B | $268M | 0.0% | 12.4% | $150M | — | $1.2B |
| Jun '22 | $4.6B | $179M | 0.0% | 11.9% | -$33M | — | $1.4B |
| Mar '22 | $4.7B | $280M | 0.0% | 13.7% | $73M | — | $1.4B |
| Dec '21 | $4.9B | $419M | 0.0% | 15.5% | $53M | — | $2.4B |
| Sep '21 | $4.9B | $578M | 0.0% | 20.7% | $321M | — | $2.3B |
| Jun '21 | $5.0B | $257M | 0.0% | 11.8% | $123M | — | $2.2B |
How the market has priced THC against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Tenet Healthcare Corp's revenue has grown 3.9% per year, and net income grown 12.5% per year. These are computed facts, not advice.
As of FY2025, Tenet Healthcare Corp reported — of total debt against $2.9B of cash; operating income covered interest expense 4.3×.
In FY2025, gross margin was —, operating margin 16.5%, and net margin 11.1%.
As of Jun '26, Tenet Healthcare Corp traded at a price-to-earnings ratio of about 6.7× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.